Entest BioMedical, a subsidiary of Bio-Matrix Scientific (BMSN), has filed a patent application for the use of adipose derived stem cells in the treatment of Chronic Obstructive Pulmonary Disease (COPD). BMSN said that it is excited with the progress achieved by Entest BioMedical in identifying diseases the company believes will be treatable through Stem Cell Therapy.
Currently, this disease is treated in similar fashion to asthma, utilizing inhalers and/or oxygen therapy. These methods are not solutions to the disease but merely provide the patient with greater level of comfort.
Dr. Steven Josephs said: “The approach is intended at the very least to alleviate the chronic inflammation in COPD. This is done by using agents known to coax adult stem cells that are delivered to the diseased lung tissue to release cytokines which in addition to the anti-inflammatory effects may actually promote the regeneration of functional lung tissue.”